Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 138 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Premenopausal Women Clear all
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Menstrual Wellness™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Menstrual Wellness in Premenopausal Women

NCT07138339
View directory record Official record
Conditions
Menstrual Wellness
Interventions
Menstrual Wellness Product Placebo Control, Menstrual Wellness Product 1
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years and older · Female only
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bone Loss in Premenopausal Women With Depression

NCT00006180
View directory record Official record
Conditions
Depression, Healthy, Osteopenia, Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 45 Years · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 1:12 AM EDT
Recruiting No phase listed Observational

The Immune System's Response to Young Women's Breast Cancer

NCT01503190
View directory record Official record
Conditions
Breast Cancer, Breast Cancer and Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 3, 2026, 1:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women

NCT01831180
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
19 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Raloxifene in Preventing Breast Cancer in Premenopausal Women

NCT00019500
View directory record Official record
Conditions
Breast Cancer
Interventions
raloxifene, evaluation of cancer risk factors
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
23 Years to 47 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 3, 2026, 1:12 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Human Epididymis Protein 4 in Normal Menstruating Women

NCT01337999
View directory record Official record
Conditions
Healthy Premenopausal Women
Interventions
blood draws
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 3, 2026, 1:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Spot Self-administered Test and Assay

NCT03840824
View directory record Official record
Conditions
Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 3, 2026, 1:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 3, 2026, 1:12 AM EDT
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 3, 2026, 1:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fat Effects in Women With Metabolic Syndrome

NCT01093560
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
fat feeding
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 3, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

NCT02811159
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Telapristone acetate
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 3, 2026, 1:12 AM EDT
Completed No phase listed Observational Results available

Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes

NCT01653210
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of a Postbiotic Supplement on Menopausal Symptoms in Premenopausal Women

NCT07570043
View directory record Official record
Conditions
Perimenopause, Menopausal Symptoms, Menopause-Related Quality of Life, Microbiome
Interventions
Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Able Biolabs, LLC
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women

NCT05336825
View directory record Official record
Conditions
Vulvodynia
Interventions
CO2 laser, Lidocaine patch 5%
Device · Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 3, 2026, 1:12 AM EDT
Active, not recruiting Not applicable Interventional

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

NCT02760849
View directory record Official record
Conditions
Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions
Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2041
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Breast Cancer Risk Biomarkers in Premenopausal Women

NCT01252277
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza™
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
25 Years to 54 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Denosumab
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 3, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional Results available

S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

NCT00088972
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Glendale, California • Albuquerque, New Mexico • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women

NCT00352157
View directory record Official record
Conditions
Skin Aging, Weight Loss
Interventions
Revival Soy Dietary Supplement
Behavioral
Lead sponsor
Physicians Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Oct 3, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03070899
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
116
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 3, 2026, 1:12 AM EDT